Exopharm Management
Management criteria checks 3/4
Exopharm's CEO is Ian Dixon, appointed in Jan 2020, has a tenure of 3.92 years. total yearly compensation is A$361.79K, comprised of 89.8% salary and 10.2% bonuses, including company stock and options. directly owns 6.43% of the company’s shares, worth A$310.84K. The average tenure of the management team and the board of directors is 2.9 years and 0.8 years respectively.
Key information
Ian Dixon
Chief executive officer
AU$361.8k
Total compensation
| CEO salary percentage | 89.8% |
| CEO tenure | 3.9yrs |
| CEO ownership | 6.4% |
| Management average tenure | 2.9yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Will Exopharm (ASX:EX1) Spend Its Cash Wisely?
May 27
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Oct 20Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Jul 02Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Apr 03Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%
Feb 09
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | AU$362k | AU$325k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$7m |
| Dec 31 2022 | n/a | n/a | -AU$7m |
| Sep 30 2022 | n/a | n/a | -AU$9m |
| Jun 30 2022 | AU$431k | AU$398k | -AU$10m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$10m |
| Sep 30 2021 | n/a | n/a | -AU$9m |
| Jun 30 2021 | AU$532k | AU$314k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$8m |
| Dec 31 2020 | n/a | n/a | -AU$7m |
| Sep 30 2020 | n/a | n/a | -AU$6m |
| Jun 30 2020 | AU$255k | AU$233k | -AU$5m |
| Mar 31 2020 | n/a | n/a | -AU$5m |
| Dec 31 2019 | n/a | n/a | -AU$5m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$198k | AU$181k | -AU$2m |
| Jun 30 2018 | AU$25k | AU$23k | -AU$175k |
Compensation vs Market: Ian's total compensation ($USD246.59K) is about average for companies of similar size in the Australian market ($USD300.74K).
Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.
CEO
Ian Dixon
3.9yrs
Tenure
AU$361,794
Compensation
Dr. Ian E. Dixon, PhD, MBA, MAICD, serves as its Chief Executive Officer and is Company Founder and Technology Co-Founder of Exopharm Limited and has been its Managing Director and Director since 2020. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | AU$361.79k | 6.43% A$ 310.8k | |
| Co-Founder & Business Services Manager | 2.9yrs | AU$238.48k | no data | |
| Senior Vice President of Finance | no data | no data | no data | |
| Company Secretary | 2.3yrs | no data | no data |
2.9yrs
Average Tenure
Experienced Management: EX1's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | AU$361.79k | 6.43% A$ 310.8k | |
| Independent Non-Executive Chairman of the Board | less than a year | AU$1.59k | no data | |
| Member of Scientific Advisory Board | no data | AU$22.47k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | less than a year | AU$9.46k | 0.0046% A$ 219.9 |
0.8yrs
Average Tenure
Experienced Board: EX1's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/30 05:16 |
| End of Day Share Price | 2023/10/02 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Exopharm Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|